Silver Book Fact

An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer was suppressed. It is also thought that it may cross the blood-brain barrier, suppressing the spread of breast cancer to the brain.

Pollack A. New Drug Holds Promise for Type of Breast Cancer. The New York Times. June 4 2006. http://www.nytimes.com/2006/06/04/health/04cancer.html?ex=1159329600&en=691f887bb3d95f4b&ei=5070

Reference

Title
New Drug Holds Promise for Type of Breast Cancer
Publication
The New York Times
Publication Date
June 4 2006
Authors
Pollack A
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • 5-Year Relative Survival Rates for Cancers in U.S.  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.  
  • Reductions in mortality for lung, female breast, prostate, and colorectal cancers accounted for 60 to 80 percent of the total decrease in all cancer deaths since the early 1990s.